Intervention
Between baseline and the six-week follow-up, the intervention group was given guidance on intake of a potassium rich diets along with potassium supplements and MRA (spironolactone or eplerenone) with the aim to increase and maintain p-K at target levels between 4.5–5.0 mmol/l according to the design of the POTCAST trial [